Endeavor BioMedicines
PrivateLast Round
Series C
Apr 24, 2024
Total Funding Raised
$295.5M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
Endeavor BioMedicines operates in Healthcare & Life Sciences and is based in San Diego, California. Its latest recorded funding round was a Series C round in April 2024.
Endeavor BioMedicines is a biotechnology company that develops precision medicines targeting the underlying genetic and cellular causes of life-threatening diseases such as pulmonary fibrosis and cancer.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Endeavor BioMedicines Comparables
Compare Endeavor BioMedicines with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Orinove Inc. | 82% | |
| Insilico Medicine | 81% | |
| Redx Pharma Plc | 79% |
For institutional investors. Book with your work email.
Endeavor BioMedicines Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series C | Apr 24, 2024 | ||||
| Series B | Feb 7, 2022 | ||||
| Series A | Jan 7, 2021 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Endeavor BioMedicines Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Longitude Capital | Series C, Series B, Series A |
| Aberdeen Group plc | Series C |
| SymBiosis Capital Management | Series C |
| Omega Funds | Series C, Series B, Series A |
| Eckuity | Series C |
| Perceptive Advisors | Series C, Series B |
| abrdn Inc. | Series C |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 27, 2026
Monthly visitors increased 68% MoM.
- May 1, 2025
Two posters accepted for American Thoracic Society 2025 International Conference.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- identified_as_competitor_ofOct 28, 2026
On Oct 28th '26, California-based Endeavor BioMedicines's taladegib could compete with Boehringer Ingelheim Pharmaceuticals, Inc.'s Ofev in the IPF market based on its potential to reduce lung fibrosis and improve lung function.
- attends_eventSep 8, 2026
Endeavor BioMedicines presents positive results from quantitative image analysis of its Phase 2a idiopathic pulmonary fibrosis trial at the ERS congress in Spain on Sep 8th '26.
- attends_eventSep 8, 2026
Endeavor BioMedicines attends the European Respiratory Society (ERS) Conference in Spain on Sep 8th '26 and presents positive results from its Phase 2a taladegib trial in idiopathic pulmonary fibrosis.
For institutional investors. Book with your work email.
Endeavor BioMedicines Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Endeavor BioMedicines's valuation, stock price, and market status.
Is Endeavor BioMedicines a public or private company?
Endeavor BioMedicines is a private company.
What is the current stock price of Endeavor BioMedicines?
Endeavor BioMedicines is a private company, so its shares have no public market price. Caplight tracks Endeavor BioMedicines's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Endeavor BioMedicines worth (valuation)?
Valuation information for Endeavor BioMedicines is not publicly available.
Can I buy Endeavor BioMedicines stock?
Endeavor BioMedicines shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Endeavor BioMedicines's last funding round?
Endeavor BioMedicines's most recent funding round was Series C on April 24, 2024.
Who are the main investors in Endeavor BioMedicines?
Key investors in Endeavor BioMedicines include Longitude Capital, Omega Funds, Avidity Partners Management, Avidity Partners, AyurMaya Capital Management Fund.
Will Endeavor BioMedicines IPO soon?
No public IPO plans have been announced for Endeavor BioMedicines.
How can I track Endeavor BioMedicines secondary market activity?
Caplight tracks bids, offers, and trades in Endeavor BioMedicines's shares on secondary markets.